Previous 10 | Next 10 |
home / stock / otlk / otlk articles
NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Outlook Therapeutics, Inc...
SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Outlook Therapeutics class action lawsuit s...
Thursday, Outlook Therapeutics Inc (NASDAQ: OTLK) announced it completed the requested Type A Meetings with the FDA to discuss the C...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Thursday. The Dow traded up 1.51% to...
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholder...
Outlook Therapeutics Inc (NASDAQ: OTLK) shares are slumping after the company announced that it has completed the requested Type A M...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 400 points on Thursday. The Dow traded up 1.21% to 33,...
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Thursday. Following the market opening Thursday, t...
ISELIN, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve FDA app...
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
Outlook Therapeutics Inc. Website:
2024-07-16 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMD Initial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025...